Homozygous familiar hypercholesterolemia: still a long way to go
- PMID: 35101174
- DOI: 10.1016/S0140-6736(21)02223-6
Homozygous familiar hypercholesterolemia: still a long way to go
Conflict of interest statement
FC has received a payment from Merck for a lecture on cardiovascular disease in women and receives fees for advisory board membership of Amgen and Sanofi, to discuss research results of PCSK9 inhibitors, all outside the area of work commented on here. RMS-H declares no competing interests.
Comment on
-
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.Lancet. 2022 Feb 19;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8. Epub 2022 Jan 28. Lancet. 2022. PMID: 35101175 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical